Neurodegenerative Change Detection
Neurodegenerative Change Detection - Related Videos
04:37
Detecting Neurodegenerative Disease-Associated Protein α-Synuclein Using ELISA
0 Views •
2025
Source: Bétemps, D., et al., Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein. J. Vis. Exp. (2015).This video demonstrates the procedure to detect neurodegenerative disease-associated protein α-synuclein in brain tissue from transgenic mice using ELISA. The steps include tissue homogenization, centrifugation, and ELISA detection of α-synuclein protein to quantify its disease-associated forms.
05:16
Detecting Histone Modifications in Yeast Cells with Neurodegenerative Protein Overexpression
0 Views •
2025
Source: Bennett, S. A., et al., Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models. J. Vis. Exp. (2019).This video demonstrates the procedure of assessing histone modifications in yeast cells overexpressing neurodegenerative proteins. The steps include cell lysis, centrifugation, electrophoresis, membrane transfer, and antibody-based detection of modified histones.
13:32
High Content Screening in Neurodegenerative Diseases
0 Views •
Cited by 8 •
2012
We describe a methodology combining automated cell culturing with high-content imaging to visualize and quantify multiple cellular processes and structures, in a high-throughput manner. Such methods can aid in the further functional annotation of genomes as well as identify disease gene networks and potential drug targets.
19:50
Interview: Protein Folding and Studies of Neurodegenerative Diseases
0 Views •
Cited by 2 •
2008
In this interview, Dr. Lindquist describes relationships between protein folding, prion diseases and neurodegenerative disorders. The problem of the protein folding is at the core of the modern biology. In addition to their traditional biochemical functions, proteins can mediate transfer of biological information and therefore can be considered a genetic material. This recently discovered function of proteins has important implications for studies of human disorders. Dr. Lindquist also...
06:30
Quantitative Analysis of Climbing Defects in a Drosophila Model of Neurodegenerative Disorders
0 Views •
Cited by 119 •
2015
We present an optimized inexpensive and reliable negative geotaxis assay in Drosophila melanogaster as a model for neurodegenerative disorders. Being more sensitive to mild locomotor defects, this assay will help screen for potential genetic interactions and drug targets.
FAQs
The key analytical challenge is separating disease-related signal from normal variation and aging. Longitudinal measurements help establish how an individual's nervous system changes over time, rather than relying on a single observation. This comparison strengthens interpretation of progressive alterations and reduces the risk of mistaking ordinary variability for neurodegenerative change.
Different data types contribute distinct evidence: brain imaging can show structural alterations, molecular biomarkers can indicate disease-associated biological processes, and cognitive or motor assessments capture changes in performance. Considering these measures together can provide a more informative picture than any single measure, supporting more confident tracking of disease-related progression.
Repeated measurement matters because early alterations may appear before symptoms become pronounced. Detecting change at that stage can help researchers evaluate whether a candidate intervention influences disease progression, rather than merely comparing treated and untreated states at one time point. This makes longitudinal detection relevant both to identifying early disease-related patterns and assessing treatment effects.
A practical workflow begins with collecting comparable measurements across time, using brain imaging, molecular biomarkers, or cognitive and motor assessments as appropriate. Researchers then compare each person's longitudinal results to distinguish progressive alteration from normal variation and aging. Integrating the findings supports interpretation of progression and creates a basis for evaluating change during studies.
Research value extends beyond observing change. Neurodegenerative change detection can support earlier diagnosis, help stratify patients into clinically or biologically meaningful groups, and aid biomarker development. By revealing patterns associated with disorders such as Alzheimer's or Parkinson's disease, these measurements also help guide investigations of interventions designed to target disease mechanisms.
In neuroscience, the approach links measurable changes in neural structure or function with the course of disease. Its relevance is especially clear when researchers seek evidence that precedes pronounced symptoms in Alzheimer's or Parkinson's disease. Comparing imaging, biomarker, cognitive, and motor data can therefore connect biological progression with observable clinical change.